Literature DB >> 29448303

Nomogram predicting the risk of recurrence after curative-intent resection of primary non-metastatic gastrointestinal neuroendocrine tumors: An analysis of the U.S. Neuroendocrine Tumor Study Group.

Katiuscha Merath1, Fabio Bagante1,2, Eliza W Beal1, Alexandra G Lopez-Aguiar3, George Poultsides4, Eleftherios Makris4, Flavio Rocha5, Zaheer Kanji5, Sharon Weber6, Alexander Fisher6, Ryan Fields7, Bradley A Krasnick7, Kamran Idrees8, Paula M Smith8, Cliff Cho9, Megan Beems9, Carl R Schmidt1, Mary Dillhoff1, Shishir K Maithel3, Timothy M Pawlik1.   

Abstract

BACKGROUND: The risk of recurrence after resection of non-metastatic gastro-entero-pancreatic neuroendocrine tumors (GEP-NET) is poorly defined. We developed/validated a nomogram to predict risk of recurrence after curative-intent resection.
METHODS: A training set to develop the nomogram and test set for validation were identified. The predictive ability of the nomogram was assessed using c-indices.
RESULTS: Among 1477 patients, 673 (46%) were included in the training set and 804 (54%) in y the test set. On multivariable analysis, Ki-67, tumor size, nodal status, and invasion of adjacent organs were independent predictors of DFS. The risk of death increased by 8% for each percentage increase in the Ki-67 index (HR 1.08, 95% CI, 1.05-1.10; P < 0.001). GEP-NET invading adjacent organs had a HR of 1.65 (95% CI, 1.03-2.65; P = 0.038), similar to tumors ≥3 cm (HR 1.67, 95% CI, 1.11-2.51; P = 0.014). Patients with 1-3 positive nodes and patients with >3 positive nodes had a HR of 1.81 (95% CI, 1.12-2.87; P = 0.014) and 2.51 (95% CI, 1.50-4.24; P < 0.001), respectively. The nomogram demonstrated good ability to predict risk of recurrence (c-index: training set, 0.739; test set, 0.718).
CONCLUSION: The nomogram was able to predict the risk of recurrence and can be easily applied in the clinical setting.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  neuroendocrine tumors; nomogram; recurrence

Mesh:

Year:  2018        PMID: 29448303      PMCID: PMC5992105          DOI: 10.1002/jso.24985

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  46 in total

1.  A single institution's 26-year experience with nonfunctional pancreatic neuroendocrine tumors: a validation of current staging systems and a new prognostic nomogram.

Authors:  Trevor A Ellison; Christopher L Wolfgang; Chanjuan Shi; John L Cameron; Peter Murakami; Liew Jun Mun; Aatur D Singhi; Toby C Cornish; Kelly Olino; Zina Meriden; Michael Choti; Luis A Diaz; Timothy M Pawlik; Richard D Schulick; Ralph H Hruban; Barish H Edil
Journal:  Ann Surg       Date:  2014-02       Impact factor: 12.969

Review 2.  Recent updates on grading and classification of neuroendocrine tumors.

Authors:  Joo Young Kim; Seung-Mo Hong; Jae Y Ro
Journal:  Ann Diagn Pathol       Date:  2017-04-13       Impact factor: 2.090

3.  Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes.

Authors:  Julie Hallet; Calvin How Lim Law; Moises Cukier; Refik Saskin; Ning Liu; Simron Singh
Journal:  Cancer       Date:  2014-10-13       Impact factor: 6.860

Review 4.  Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus.

Authors:  Simron Singh; Sylvia L Asa; Chris Dey; Hagen Kennecke; David Laidley; Calvin Law; Timothy Asmis; David Chan; Shereen Ezzat; Rachel Goodwin; Ozgur Mete; Janice Pasieka; Juan Rivera; Ralph Wong; Eva Segelov; Daniel Rayson
Journal:  Cancer Treat Rev       Date:  2016-05-17       Impact factor: 12.111

Review 5.  The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society.

Authors:  James R Howe; Kenneth Cardona; Douglas L Fraker; Electron Kebebew; Brian R Untch; Yi-Zarn Wang; Calvin H Law; Eric H Liu; Michelle K Kim; Yusuf Menda; Brian G Morse; Emily K Bergsland; Jonathan R Strosberg; Eric K Nakakura; Rodney F Pommier
Journal:  Pancreas       Date:  2017-07       Impact factor: 3.327

Review 6.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

7.  Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery.

Authors:  A E Slagter; D Ryder; B Chakrabarty; A Lamarca; R A Hubner; W Mansoor; D A O'Reilly; P E Fulford; H J Klümpen; J W Valle; M G McNamara
Journal:  Surg Oncol       Date:  2016-05-26       Impact factor: 3.279

Review 8.  Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature.

Authors:  Shahrokh F Shariat; Pierre I Karakiewicz; Nazareno Suardi; Michael W Kattan
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

9.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

10.  Epidemiology and classification of gastroenteropancreatic neuroendocrine neoplasms using current coding criteria.

Authors:  O M Sandvik; K Søreide; E Gudlaugsson; J T Kvaløy; J A Søreide
Journal:  Br J Surg       Date:  2015-10-29       Impact factor: 6.939

View more
  10 in total

Review 1.  Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2019-11-27       Impact factor: 4.512

2.  A Multi-institutional International Analysis of Textbook Outcomes Among Patients Undergoing Curative-Intent Resection of Intrahepatic Cholangiocarcinoma.

Authors:  Katiuscha Merath; Qinyu Chen; Fabio Bagante; Sorin Alexandrescu; Hugo P Marques; Luca Aldrighetti; Shishir K Maithel; Carlo Pulitano; Matthew J Weiss; Todd W Bauer; Feng Shen; George A Poultsides; Olivier Soubrane; Guillaume Martel; B Groot Koerkamp; Alfredo Guglielmi; Endo Itaru; Jordan M Cloyd; Timothy M Pawlik
Journal:  JAMA Surg       Date:  2019-06-19       Impact factor: 14.766

Review 3.  Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature.

Authors:  S M Sadowski; C R C Pieterman; N D Perrier; F Triponez; G D Valk
Journal:  Endocr Relat Cancer       Date:  2020-06       Impact factor: 5.678

4.  Trends of incidence and prognosis of gastric neuroendocrine neoplasms: a study based on SEER and our multicenter research.

Authors:  Ping Hu; Jian'an Bai; Min Liu; Jingwen Xue; Tiaotiao Chen; Rui Li; Xiaoling Kuai; Haijian Zhao; Xiaolin Li; Ye Tian; Wei Sun; Yujia Xiong; Qiyun Tang
Journal:  Gastric Cancer       Date:  2020-02-05       Impact factor: 7.370

5.  Prognostic importance of lymph node yield after curative resection of gastroenteropancreatic neuroendocrine tumours.

Authors:  Jaseela Chiramel; Rose Almond; Astrid Slagter; Adeel Khan; Xin Wang; Kok Haw Jonathan Lim; Melissa Frizziero; Bipasha Chakrabarty; Annamaria Minicozzi; Angela Lamarca; Wasat Mansoor; Richard A Hubner; Juan William Valle; Mairéad Geraldine McNamara
Journal:  World J Clin Oncol       Date:  2020-04-24

6.  Predicting the Survival Probability of Neuroendocrine Tumor Populations: Developing and Evaluating a New Predictive Nomogram.

Authors:  Jian-Xian Chen; Yan Lin; Yi-Liang Meng; Ai-Xia Zhao; Xiao-Juan Huang; Rong Liang; Yong-Qiang Li; Zhi-Hui Liu
Journal:  Biomed Res Int       Date:  2021-01-28       Impact factor: 3.411

7.  Patterns of Lymph Node Metastasis and Optimal Surgical Strategy in Small (≤20 mm) Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Yibo Cai; Zhuo Liu; Lai Jiang; Dening Ma; Zhenyuan Zhou; Haixing Ju; Yuping Zhu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-21       Impact factor: 6.055

8.  Establishment and validation of a clinicopathological prognosis model of gastroenteropancreatic neuroendocrine carcinomas.

Authors:  Jing Chen; Yibing Liu; Ke Xu; Fei Ren; Bowen Li; Hong Sun
Journal:  Front Oncol       Date:  2022-09-26       Impact factor: 5.738

9.  Identifying Risk Factors and Patterns for Early Recurrence of Pancreatic Neuroendocrine Tumors: A Multi-Institutional Study.

Authors:  Charlotte M Heidsma; Diamantis I Tsilimigras; Flavio Rocha; Daniel E Abbott; Ryan Fields; George A Poultsides; Clifford S Cho; Alexandra G Lopez-Aguiar; Zaheer Kanji; Alexander V Fisher; Bradley A Krasnick; Kamran Idrees; Eleftherios Makris; Megan Beems; Casper H J van Eijck; Elisabeth J M Nieveen van Dijkum; Shishir K Maithel; Timothy M Pawlik
Journal:  Cancers (Basel)       Date:  2021-05-07       Impact factor: 6.639

10.  Accuracy of Grading in Pancreatic Neuroendocrine Neoplasms and Effect on Survival Estimates: An Institutional Experience.

Authors:  Nikolaos A Trikalinos; Deyali Chatterjee; Jane Lee; Jingxia Liu; Greg Williams; William Hawkins; Chet Hammill
Journal:  Ann Surg Oncol       Date:  2020-03-23       Impact factor: 4.339

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.